Key result
This review discusses the literature on prasugrel that has emerged since the TRITON-TIMI 38 trial, which showed prasugrel had superior efficacy to clopidogrel but increased bleeding risk.
This review summarizes the literature on the efficacy and safety profile of prasugrel that has emerged since the pivotal TRITON-TIMI 38 trial.
Synthesizes post-TRITON prasugrel data; extends evidence synthesis for refined efficacy-bleeding assessments in research and practice.
Prasugrel, a third-generation thienopyridine antiplatelet agent, demonstrated superior efficacy to clopidogrel but with an increased risk of bleeding in the phase III pivotal registration Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction (TRITON-TIMI 38). This article reviews and discusses select components of a large literature of prasugrel data that has emerged since the TRITON-TIMI 38 (TRITON) study primary disclosure.
No takes yet. Share an insight, caveat, or question.
Jakubowski et al. (2011) reported a review. Prasugrel vs. Clopidogrel was evaluated. This review discusses the literature on prasugrel that has emerged since the TRITON-TIMI 38 trial, which showed prasugrel had superior efficacy to clopidogrel but increased bleeding risk.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: